Suzanne Shusterman

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

Suzanne Shusterman, Wendy B. London, Stephen D. Gillies et al. · Journal of Clinical Oncology · 2010 · 242 citations · Full text

Medicine, Oncology, Pharmacology +13

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors

Marian H. Harris, Steven G. DuBois, Julia Glade Bender et al. · JAMA Oncology · 2016 · 204 citations · Full text

Medicine, Oncology, Pediatrics +17

Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy Number

Qun Wang, Sharon J. Diskin, Eric Rappaport et al. · Cancer Research · 2006 · 201 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14

Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

David Delgado, Jacquelyn A. Hank, Jill Kolesar et al. · Cancer Research · 2010 · 176 citations · Full text

Life Sciences, Immunology, Oncology +17

A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma

Deepa Kolaseri Krishnadas, Suzanne Shusterman, Fanqi Bai et al. · Cancer Immunology Immunotherapy · 2015 · 173 citations · Full text

Medicine, Immunology, Oncology +14